Getinge said Tuesday it will phase out its surgical perfusion business and reallocate resources to higher-growth areas such as extracorporeal membrane oxygenation (ECMO) and transplant care. CEO ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S. (Reuters) ...

Narrow-moat Getinge GETI B reported third-quarter earnings above our expectations. We are increasing our fair value estimate to SEK 247 from SEK 221, as Getinge is executing a turnaround in its acute ...

GOTHENBURG, Sweden, Sept. 30, 2020 /PRNewswire/ -- Born 12 weeks too early with a 50/50 chance at survival, Sabina Checketts has grown up to become a neonatal doctor herself, using new therapies and ...

GÖTEBORG, Sweden, July 24, 2020 /PRNewswire/ -- Today Getinge announces its intention to become a CO₂neutral company by 2025. The target will be reached by a stepwise approach in several areas and ...

Q3 adj. EBITA and sales miss analysts' forecasts Orders keep growing organically at 7.4% Deliveries restarted after temporary disruptions in Q3, CEO says Shares fall 6.9% by midday local time Oct 18 ...

Getinge’s GETI B recent litany of regulatory, quality, and supply chain troubles across multiple products provides us with a flashback to 2013-2015 when similar issues culminated in a consent decree ...

BOSTON--(BUSINESS WIRE)--Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and ...

* GETINGE CEO: NORMALISATION IN CHINA IS SLOWLY BUT SURELY HAPPENING AFTER COVID BUT WE DON'T SEE A STRONG RECOVERY OR STRONG POSITIVE IMPACT YET * GETINGE CEO: WE EXPECT MIXED PERFORMANCE FROM CHINA ...

GETINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Getinge Group (STO:GETIB) has recently performed a strategic review to clarify its long-term strategy for ensuring sustainable and profitable growth.